Efficacy of switching therapy of luteinizing hormone–releasing hormone analogue for advanced prostate cancer

Efficacy of switching therapy of luteinizing hormone–releasing hormone analogue for advanced prostate cancer

Show other versions (1)

This study was conducted to determine the efficacy of switching therapy with a second-line luteinizing hormone–releasing hormone (LHRH) analogue after prostate-specific antigen (PSA) progression for advanced prostate cancer. We enrolled 200 patients, from December 2005 to September 2013, with nodal...

Full description

Bibliographic Details
Main Authors:	Yuan-Chi Shen, Chih- Hsiung Kang, Po-Hui Chiang
Format:	Article
Language:	English
Published:	Wiley 2016-11-01
Series:	Kaohsiung Journal of Medical Sciences
Subjects:	Goserelin Leuprorelin Prostate cancer Prostate-specific antigen
Online Access:	http://www.sciencedirect.com/science/article/pii/S1607551X16302583

Similar Items

Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide
by: Myungsun Shim, et al.
Published: (2019-07-01)

INTERMITTENT HORMONE THERAPY WITH ELIGARD IN PATIENTS WITH PROSTATE CANCER
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)

INTERMITTENT HORMONE THERAPY WITH ELIGARD IN PATIENTS WITH PROSTATE CANCER
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)

The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy
by: I. G. Rusakov, et al.
Published: (2020-12-01)

Adjuvant hormone therapy in patients undergoing high-intensity focused ultrasound therapy for locally advanced prostate cancer
by: A. I. Neimark, et al.
Published: (2014-11-01)

Adjuvant hormone therapy in patients undergoing high-intensity focused ultrasound therapy for locally advanced prostate cancer
by: A. I. Neimark, et al.
Published: (2014-11-01)

Unsuspected skin metastasis of adenocarcinoma of the prostate in a patient on goserelin (Zoladex)
by: Timothy Uzoma Mbaeri, et al.
Published: (2018-01-01)

Pharmacoeconomic analysis of leuprolide acetate (Eligard) 45 mg once in 6 months for advanced prostate cancer in Russian Federation
by: M. Yu. Frolov, et al.
Published: (2015-12-01)

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
by: Rajni Sethi, et al.
Published: (2009-06-01)

Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade
by: Vojinov Saša, et al.
Published: (2011-01-01)

Luteinizing hormone releasing hormone analogues in the treatment of patients with prostate cancer
by: B. Ya. Alexeev, et al.
Published: (2018-11-01)

Efficacy of switching therapy of luteinizing hormone-releasing hormone analogue for advanced prostate cancer
by: Yuan-Chi Shen, et al.
Published: (2015-06-01)

THE USE OF MODERN ANALOGUES OF LUTEINIZING HORMONE RELEASING HORMONE IN THE HORMONAL THERAPY IN PATIENTS WITH PROSTATE CANCER
by: E. Yu. Safronova, et al.
Published: (2017-06-01)

Intermediate results of the observational program on the Eligard (45 mg) administration in the clinical practice
by: V. B. Matveev, et al.
Published: (2016-06-01)

Final results of the prospective multicenter observational program RU-EGD-NI-001 for evaluation of efficacy and tolerability of the 6-month depot Eligard 45 mg in patients with advanced prostate carcinoma in routine clinical practice of uro-oncologists in the Russian Federation
by: V. B. Matveev, et al.
Published: (2017-06-01)

BEAM THERAPY AND LONG-TERM HORMONAL THERAPY IN PATIENTS WITH PROSTATE CANCER
by: A. O. Karyakin, et al.
Published: (2014-07-01)

BEAM THERAPY AND LONG-TERM HORMONAL THERAPY IN PATIENTS WITH PROSTATE CANCER
by: A. O. Karyakin, et al.
Published: (2014-07-01)

Review of Clinical Manifestations of Biochemically-advanced Prostate Cancer Cases
by: Edmund Chiong, et al.
Published: (2005-07-01)

Identification of predictors based on drug targets highlights accurate treatment of goserelin in breast and prostate cancer
by: Yue Zhao, et al.
Published: (2021-01-01)

Advanced prostatic carcinomas with low serum levels of prostate-specific antigen
by: Cerović Snežana J., et al.
Published: (2002-01-01)

Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
by: Tunn UW, et al.
Published: (2013-04-01)

Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review
by: Arslaan Javaeed, et al.
Published: (2020-05-01)

Analysis of the Correlationship between Prostate Specific Antigen Related Variables and Risk Factor in Patients with Prostate Carcinoma
by: Daoyuan Wang, et al.
Published: (2015-01-01)

Free prostate-specific antigen outperforms total prostate-specific antigen as a predictor of prostate volume in patients without prostate cancer
by: Sinan Avci, et al.
Published: (2020-04-01)

The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer
by: Bai X, et al.
Published: (2020-08-01)

Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer
by: Ahmad Anies Shahab, et al.
Published: (2013-03-01)

Restart of androgen deprivation therapy after goserelin induced pituitary apoplexy in a patient with disseminated prostate cancer a case report and five-years follow-up
by: Belal Aljabri, et al.
Published: (2021-07-01)

CURRENT APPROACHES TO TREATING HORMONE REFRACTORY PROSTATE CANCER
by: O. B. Karyakin
Published: (2014-07-01)

CURRENT APPROACHES TO TREATING HORMONE REFRACTORY PROSTATE CANCER
by: O. B. Karyakin
Published: (2014-07-01)

Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy
by: Yong Jin Kang, et al.
Published: (2017-11-01)

CUT-OFF POINT OF PSA AND PSA DENSITY IN PROSTATE CANCER SUSPECTED PATIENTS
by: Daniel Simanjuntak, et al.
Published: (2016-03-01)

Elevated prostate volume index and prostatic chronic inflammation reduce the number of positive cores at first prostate biopsy set: results in 945 consecutive patients
by: Antonio B. Porcaro, et al.

Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy
by: Pinkawa Michael, et al.
Published: (2012-12-01)

Moving ahead of prostate-specific antigen
by: Banyameen Mohamad Iqbal, et al.
Published: (2016-01-01)

Prostate-specific antigen density predicts favorable pathology and biochemical recurrence in patients with intermediate-risk prostate cancer
by: Ho Won Kang, et al.
Published: (2016-01-01)

Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia
by: Yasuhide Kitagawa, et al.
Published: (2015-06-01)

Association of prostate volume with incidence and aggressiveness of prostate cancer
by: Al-Khalil S, et al.
Published: (2016-10-01)

DIAGNOSIS OF PROSTATIC NEOPLASM LATER TO ANTIBIOTIC TREATMENT IN PATIENTS WITH PROSTATE-SPECIFIC ANTIGEN BETWEEN 4 AND 10 ng/ml (IN SPANISH)
by: Infantes-Burgos Ronald Javier, et al.
Published: (2014-01-01)

Is It Effective to Perform Two More Prostate Biopsies According to Prostate-Specific Antigen Level and Prostate Volume in Detecting Prostate Cancer? Prospective Study of 10-Core and 12-Core Prostate Biopsy
by: Byung Il Yoon, et al.
Published: (2012-05-01)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
by: Michael Tzeng, et al.
Published: (2021-08-01)

Cannot write session to /tmp/vufind_sessions/sess_ka6a7fk1a2uopocc4qfb02h2fe